Erk1/2 MAP kinases are required for epidermal G2/M progression by Dumesic, Phillip A. et al.
JCB: ARTICLE
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 185 No. 3  409–422
www.jcb.org/cgi/doi/10.1083/jcb.200804038 JCB 409
Correspondence to Paul A. Khavari: khavari@stanford.edu
Abbreviations used in this paper: CA, constitutively active; Erk, extracellular   
signal-regulated kinase; GO, gene ontology; PI, propidium iodide; Mek, MAPK/
Erk kinase; Rsk, ribosomal S6 kinase; WT, wild type.
Introduction
The Erk1/2, JNK, p38, Erk3/4, Erk5, Erk6, and Erk7/8 cascades 
are among the major MAPK pathways in mammals. The Erk1/2 
MAPK pathway is a kinase cascade that includes Raf MAPK 
kinase kinases (Raf1, B-Raf, and A-Raf), MAPK/extracellular 
signal-regulated kinase (Erk; Mek) MAPK kinases (Mek1 and 
Mek2), and Erk MAPKs (Erk1 and Erk2 [Erk1/2]). Together, 
these proteins translate extracellular cues into changes in gene 
expression and protein activity (Chambard et al., 2007). In this 
pathway, Ras GTPases are activated by receptor engagement, 
causing recruitment of Raf to the cell membrane for phosphory-
lation (Shaul and Seger, 2007). Activated Raf then phosphory-
lates Mek1/2, which in turn activates Erk1/2, leading to the 
phosphorylation of >160 known nuclear and cytosolic Erk1/2 
substrates (Yoon and Seger, 2006). Erk1/2 exert pleiotropic effects, 
which are perturbed in many disease states, including human   
cancers, of which 30% show Erk hyperactivation (Hoshino   
et al., 1999).
Analysis of the Erk1/2 MAPK cascade is complicated by 
the existence of various isoforms possessing both overlapping 
and unique functions. However, recently, the effect of genetic ab-
rogation of an entire level of the MAPK cascade was determined 
by the generation of skin-specific MEK1/2 double knockout mice 
(Scholl et al., 2007). Whereas mice lacking either MEK1 or MEK2 
alone were normal, double knockout mice died shortly after birth 
from dehydration secondary to epidermal hypoplasia and hypo-
proliferation. Inducible knockout of MEK1/2 in adult mouse skin 
similarly led to epidermal hypoplasia, hypoproliferation, and 
apoptosis, establishing the Erk1/2 MAPK cascade as a prerequi-
site for tissue development and homeostasis and highlighting the 
importance of identifying the downstream effectors important for 
this activity.
The only known substrates of Mek1/2 are the serine-
threonine kinases Erk1 and Erk2, also known as p44 MAPK and 
p42 MAPK, respectively (Kohno and Pouysségur, 2006). Erk1 
and Erk2 share 83% amino acid sequence identity and have 
been traditionally considered functionally redundant (Pouysségur 
and Lenormand, 2003). However, recent evidence has revealed 
multiple scaffolding proteins such as MP1 that sequester the in-
dividual Erk isoforms preferentially, suggesting unique roles for 
the isoforms (Brahma and Dalby, 2007). Indeed, ERK1 knock-
out mice are viable, whereas ERK2 knockout mice die during 
embryogenesis and display defects in trophoblast formation and 
  E
rk1/2  mitogen-activated  protein  kinases  (MAPKs) 
are often hyperactivated in human cancers, where 
they affect multiple processes, including prolifera-
tion. However, the effects of Erk1/2 loss in normal epithe-
lial tissue, the setting of most extracellular signal-regulated 
kinase (Erk)–associated neoplasms, are unknown. In epi-
dermis, loss of Erk1 or Erk2 individually has no effect, 
whereas simultaneous Erk1/2 depletion inhibits cell divi-
sion, demonstrating that these MAPKs are necessary for 
normal tissue self-renewal. Growth inhibition caused by 
Erk1/2 loss is rescued by reintroducing Erk2, but not by 
activating Erk effectors that promote G1 cell cycle pro-
gression.  Unlike  fibroblasts,  in  which  Erk1/2  loss  de-
creases cyclin D1 expression and induces G1/S arrest, 
Erk1/2 loss in epithelial cells reduces cyclin B1 and c-Fos 
expression and induces G2/M arrest while disrupting a 
gene  regulatory  network  centered  on  cyclin  B1–Cdc2. 
Thus, the cell cycle stages at which Erk1/2 activity is re-
quired vary by cell type, with Erk1/2 functioning in epi-
thelial cells to enable progression through G2/M.
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for Erk1/2 in distinct cell types and identify these MAPKs as re-
quired regulators of G2/M progression in the epidermis.
Results
Erk1/2 are required for epidermal 
proliferation
To investigate the roles of Erk1 and Erk2 in epidermal homeostasis, 
we used RNAi to deplete Erk1, Erk2, or both in human epidermis 
in vivo. Primary human keratinocytes were electroporated with 
siRNA targeting ERK1 or ERK2, which depleted expression of 
these proteins either individually or together (Fig. 1 A). To generate 
skin lacking Erk1/2, siRNA-treated keratinocytes were seeded onto 
devitalized human dermis and then grafted onto immunodeficient 
mice (Scholl et al., 2007). By 6 d after grafting, keratinocytes 
treated with scrambled control siRNA had generated full thickness 
epidermis marked by stratification and differentiation analogous to 
that of normal human skin. Immunofluorescence staining with a 
species-specific antibody against human desmoglein 3 confirmed 
that the analyzed tissue was of human origin, and antibodies against 
keratin 10 and transglutaminase 1 revealed proper suprabasal local-
ization of these differentiation markers. Furthermore, 1 integrin, a 
marker normally expressed by keratinocytes contiguous to the 
basement membrane, and Ki-67, a marker of cell proliferation, 
were confined to the basal layer, as in normal human skin. Keratin 5, 
a marker of basal layer keratinocytes, was expressed throughout 
the epidermis, as previously observed in regenerated tissue at this 
time point (Fig. 1 C; Scholl et al., 2007).
Epidermis depleted of either Erk1 or Erk2 individually was 
indistinguishable from control epidermis, whereas epidermis lack-
ing both Erk1 and Erk2 was markedly hypoplastic, with 68% fewer 
basal layer cells than control skin (P < 0.01). Immunohistochemical 
staining confirmed that Erk1/2 protein was depleted in Erk1/2 
double knockdown epidermis (Fig. S1 A). Cells in Erk1/2-depleted 
epidermis were not only fewer in number than in control skin but 
also less likely to be undergoing mitosis, with a mitotic index sig-
nificantly lower than that of control skin (17 vs. 53%; Fig. 1 B). 
Although thin, Erk1/2 double knockdown epidermis maintained 
normal suprabasal expression of differentiation markers, including 
transglutaminase 1 and keratin 10, along with morphologically 
normal stratum corneum (Fig. 1 C). In addition, apoptosis was not 
detected in Erk1/2 double knockdown epidermis nor was it ob-
served in skin treated with any other siRNA, as assessed by TUNEL 
assay (Fig. S1 B). Thus, whereas epidermal proliferation proceeds 
normally in the absence of either Erk1 or Erk2, depletion of both 
gene products together leads to hypoplasia and hypoproliferation 
without affecting differentiation or cell viability.
To confirm that the impacts of Erk1/2 loss were specific to 
the loss of Erk1 and Erk2 rather than an off-target effect, we tested 
whether a constitutively active (CA) Erk2 (Erk2-CA) construct 
could rescue the phenotype of combined Erk1/2 depletion. Kera-
tinocytes were infected with retroviral vectors encoding Erk2-CA 
or, as a control, LacZ; 2 d later, the cells were electroporated with 
scrambled siRNA or Erk1/2 siRNA and used to generate human 
skin grafts (Scholl et al., 2007). The Erk2-CA construct contains 
two mismatches within the Erk2 siRNA–binding site and there-
fore was not efficiently silenced by Erk1/2 siRNA (Fig. 2 A). 
mesoderm  differentiation  (Hatano  et  al.,  2003;  Saba-El-Leil   
et al., 2003; Yao et al., 2003). Further studies in ovarian cells,   
fibroblasts, hepatocytes, and thymocytes have identified differ-
ential roles for Erk1 and Erk2 in the control of cell survival and 
proliferation, emphasizing the importance of cell type in the 
analysis of Erk function (Fischer et al., 2005; Zeng et al., 2005; 
Vantaggiato et al., 2006; Fremin et al., 2007).
Among the biological processes influenced by Erk1/2 is 
cell cycle progression, a mechanism best studied in nonepithelial 
cell lines. For example, in mesenchymal fibroblasts, Erk1/2 were 
first identified as a result of their activation by mitogens, with Erk 
activity throughout G1 phase being required for G1/S-phase cell 
cycle progression (Meloche and Pouysségur, 2007). In this con-
text, Erk1/2 influence G1/S transition in myriad ways, including 
up-regulation and stabilization of cyclin D1, up-regulation of p21 
expression with attendant stabilization of cyclin D–Cdk4 com-
plexes, and down-regulation of antiproliferative genes, including 
Sox6 and Jund1 (Lavoie et al., 1996; Cheng et al., 1999; Yamamoto 
et al., 2006). Roles for Erk signaling in later stages of the cell 
cycle such as G2/M progression are controversial, with discrep-
ancies regarding Erk1/2 activity during this stage and the obser-
vation that pharmacologic Mek inhibition causes off-target 
effects that perturb G2/M progression (Roberts et al., 2002; Liu   
et al., 2004; Shinohara et al., 2006; Kim et al., 2008). Moreover, al-
though most Erk1/2 cell cycle effects have been studied in fibro-
blast cell lines, Erk1/2 function in epithelial tissues, which are a 
major site of Erk activation in neoplasia, is less well understood.
In  the  self-renewing  epithelia  of  the  epidermis,  Erk1/2 
MAPK signaling appears to promote proliferation of basal layer 
stem cells and to suppress normal differentiation of suprabasal 
layer cells. Activation of Harvey Ras, Raf1, or Mek1 in mouse and 
human skin induces epidermal hyperplasia marked by hyperprolif-
eration and reduced differentiation (Tarutani et al., 2003; Scholl   
et al., 2004). Moreover, most spontaneous epidermal squamous 
cell carcinomas, which are marked by characteristics of basal layer 
cells, including integrin expression and proclivity toward prolifera-
tion over differentiation, exhibit Ras induction and MAPK cascade 
hyperactivity (Dajee et al., 2003). Mouse experiments showing that 
expression of dominant-negative Ras in basal layer skin causes 
hypoplasia and lethality, whereas Ras blockade in suprabasal 
keratinocytes has no effect, further support a specific role for 
Erk1/2 MAPK signaling in the mitotically active basal compart-
ment (Dajee et al., 2002). However, the downstream mechanisms 
by which the Erk1/2 MAPK cascade sustains proliferation in epi-
thelial cells remain unclear.
In this study, we investigate the roles of Erk1 and Erk2 in 
human epidermis. We report that depletion of Erk1 or Erk2 alone 
does not disrupt epidermal proliferation or differentiation, whereas 
simultaneous depletion of Erk1 and Erk2 induces hypoplasia and 
hypoproliferation  without  disrupting  differentiation.  Effects  of 
Erk1/2 loss are not rescued by activation of the Erk1/2 effectors 
Rsk1 or cyclin D1, suggesting action of alternate Erk1/2 targets. 
Indeed, Erk1/2-depleted epidermal cells exhibit a G2/M cell cycle 
arrest with decreased expression of the transcription factor c-Fos 
and its target gene cyclin B1. These effects are not observed in fibro-
blasts, which display G1/S arrest with decreased cyclin D1 expres-
sion upon Erk1/2 depletion. Our findings establish differential roles 411 ERK1/2 SUSTAIN G2/M PROGRESSION • Dumesic et al.
Erk1/2 loss is not rescued by activation of 
Rsk1 or G1/S cell cycle regulators
Erk MAPK signaling is highly pleiotropic, with >160 Erk1/2 
substrates identified (Yoon and Seger, 2006). One major subset of 
effectors is the ribosomal S6 kinase (Rsk) family of kinases, 
which regulate cell growth (via phosphorylation of polyribosomal 
proteins) as well as progression through multiple stages of the 
cell cycle (via phosphorylation of Myt1 and AP-1 transcription 
Whereas LacZ expression did not affect Erk1/2 knockdown or its 
associated tissue phenotype, expression of Erk2-CA fully reversed 
the hypoplasia and hypoproliferation characteristic of Erk1/2 de-
pletion (Fig. 2, B and C). In a separate experiment, overexpres-
sion of wild-type (WT) rat Erk2 (Erk2-WT) was also able to fully 
rescue the effects of Erk1/2 knockdown, confirming that this 
phenotype is specifically caused by the loss of MAPK cascade 
signaling components (Fig. S2, A–C).
Figure 1.  Combined Erk1/2 depletion inhibits proliferation in human epidermal tissue. (A) Immunoblot of keratinocyte extracts 4 d after electroporation 
with the indicated siRNA stained with the antibodies indicated on the right. (B) Mitotic indices of skin grafts comprising keratinocytes treated with the 
indicated siRNA oligomers. n = 3–5 grafts per genotype; mean ± SEM; *, P < 0.01 versus control. (C) Human skin tissue engineered with the indicated 
siRNAs, harvested 6 d after grafting, and stained with species-specific antibody against human desmoglein 3 (Dsg3; green), Ki-67, 1 integrin, keratin 5, 
keratin 10, and transglutaminase 1 (TGase1; orange) and the nuclear counterstain Hoechst 33342 (blue). Bars, 50 µm.JCB • VOLUME 185 • NUMBER 3 • 2009   412
loss, we expressed CA Rsk1 (Rsk1-CA) in the context of com-
bined Erk1/2 knockdown (Fig. 3 B). Keratinocytes were in-
fected with retroviral vectors encoding LacZ or Rsk1-CA, after 
which they were treated with either a scrambled control siRNA 
or siRNA against ERK1/2 and used to generate skin grafts. 
factors;  Frodin  and  Gammeltoft,  1999).  Immunoblotting 
showed that Erk1/2 depletion led to reduced Rsk1 activation in 
keratinocytes, confirming that Rsk is a substrate of Erk1/2 in 
human epidermis (Fig. 3 A). To determine whether Rsk activa-
tion could rescue the epidermal effects of combined Erk1/2 
Figure 2.  Active Erk2 rescues the effects of Erk1/2 depletion in human skin. (A) Immunoblot of keratinocyte extracts after transduction by the indicated 
retroviral vectors and electroporation with the indicated siRNAs stained with the antibodies listed on the right. (B) Mitotic indices of skin grafts comprising 
keratinocytes treated with the indicated siRNA and retroviral vectors. n = 3 grafts per genotype; mean ± SEM; *, P < 0.01 versus control. (C) Human skin 
tissue comprising keratinocytes treated with the indicated siRNA and retroviral vectors, harvested 6 d after grafting, and stained with the antibodies listed 
on the right (orange or green) as well as the nuclear counterstain Hoechst 33342 (blue). Bars, 50 µm.413 ERK1/2 SUSTAIN G2/M PROGRESSION • Dumesic et al.
hypoplasia, and normal differentiation (Fig. 3, C and D). Thus, 
Rsk1, a single effector arm of MAPK signaling, is insufficient to 
rescue the epidermal impacts of Erk1/2 loss.
Erk1/2-depleted epidermis expressing Rsk1-CA showed a pheno-
type indistinguishable from that induced by Erk1/2 depletion 
in LacZ-expressing keratinocytes: namely, hypoproliferation, 
Figure 3.  Active Rsk1 does not rescue the effects of epidermal Erk1/2 depletion. (A) Immunoblot of keratinocyte extracts 4 d after electroporation with the 
indicated siRNA stained with the antibodies listed on the right. (B) Immunoblot of keratinocyte extracts after transduction by the indicated retroviral vectors 
and electroporation with the indicated siRNAs stained with the antibodies listed on the right. (C) Mitotic indices of skin grafts comprising keratinocytes 
treated with the indicated siRNA and retroviral vectors. n = 3–4 grafts per genotype; mean ± SEM; *, P < 0.01 versus control. (D) Human skin tissue 
comprising keratinocytes treated with the indicated siRNA and retroviral vectors, harvested 6 d after grafting, and stained with the antibodies listed on the 
right (orange or green) as well as the nuclear counterstain Hoechst 33342 (blue). Bars, 50 µm.JCB • VOLUME 185 • NUMBER 3 • 2009   414
Surprisingly, keratinocytes lacking both Erk1 and Erk2 were 
markedly enriched in cells with a 4-N DNA content (33.7 vs. 
19.9%), indicating that Erk1/2 loss leads to arrest in the G2/M 
phase of the cell cycle.
Because these results differed from the previously pub-
lished G1 arrest observed with Erk1/2 blockade in mesenchymal 
cells (Meloche and Pouysségur, 2007), we investigated the effect 
of Erk1/2 depletion on the cell cycle of primary human skin fibro-
blasts. Erk1/2 siRNA robustly reduced Erk1/2 protein expression 
(Fig. 5 E) and reduced cell proliferation as compared with fibro-
blasts treated with control siRNA (not depicted). Combined 
Erk1/2 depletion decreased the proportion of cells in S phase and 
increased the proportion of cells in G1 phase, as compared with 
control cells, indicating G1-phase arrest (Fig. 5 F). Consistent 
with a previous study (Villanueva et al., 2007), this G1 arrest was 
associated with decreased cyclin D1 expression (Fig. 5 G) and 
could be rescued by overexpressing cyclin D1 and Cdk4-C24 
(Fig. S3 A). In contrast, Erk1/2 knockdown in keratinocytes was 
not associated with decreased cyclin D1 expression (Fig. 4 A), 
and overexpression of cyclin D1 and Cdk4-C24 had no effect on 
the cell cycle blockade induced by Erk1/2 depletion (Fig. S3 B). 
Importantly, both cell types express similar levels of cyclin D1 
before Erk1/2 knockdown when compared directly (Fig. S3 C). 
Thus, Erk1/2 affect cell cycle progression in a cell type–specific 
manner, with Erk1/2 loss causing G1 and G2/M arrest in fibro-
blasts and keratinocytes, respectively.
Erk1/2 loss in epithelial cells alters 
expression of a G2/M regulatory network
To investigate changes in gene expression associated with Erk1/2 
loss in epidermal cells, we undertook gene expression profiling 
on cells treated with either scrambled control siRNA or each of 
two unique pairs of siRNA oligomers targeting ERK1 and ERK2. 
To determine the core set of genes regulated by Erk1/2 signaling 
and to eliminate gene changes that represent off-target siRNA 
effects, we isolated genes that met the following criteria: (a) ex-
pression level significantly altered (analysis of variance, P < 
0.01) by both pairs of Erk1/2 siRNAs, as compared with control 
cells, and (b) expression level altered in the same direction by 
both pairs of Erk1/2 siRNAs, as compared with control cells. 
These criteria isolated 1,205 genes, which were subsequently 
sorted by hierarchical clustering on expression level (Fig. 6 A). 
As expected, down-regulated genes included ERK1 and ERK2, 
as well as genes that agreed with previously reported effects of 
pharmacologic MAPK inhibition (Fig. 6 A; Yamamoto et al., 
2006; Gazel et al., 2008).
Gene ontology (GO) term analysis revealed that the top 
seven most enriched biological process GO terms in this set of 
1,205 genes were all related to cell cycle progression (Fig. 6 B). 
Importantly, these terms included three mitosis-specific terms, 
which is consistent with the G2/M arrest observed in Erk1/2-
depleted keratinocytes. No G1/S-specific GO terms were signif-
icantly enriched in this gene set, and examining expression of 
core G1/S regulators, including cyclin D1 and Cdk4, revealed 
no change with Erk1/2 knockdown, indicating that the primary 
effects of Erk1/2 knockdown in keratinocytes were specific to 
the G2/M cell cycle stages (Fig. S4 A).
We next investigated whether the proliferation defect of 
Erk1/2-depleted keratinocytes could be rescued by promoting 
cell cycle progression via core cell cycle machinery. In fibro-
blasts, Erk1/2 MAPK signaling promotes G1/S progression by 
up-regulating cyclin D1 expression: in cultured fibroblasts, cy-
clin D1 overexpression rescues G1 arrest induced by pharmaco-
logic MAPK inhibition (Villanueva et al., 2007). To determine 
whether cyclin D1 overexpression could rescue epidermal hypo-
plasia caused by Erk1/2 depletion, keratinocytes transduced with 
retroviral vectors encoding either LacZ or cyclin D1 were treated 
with scrambled siRNA or siRNA against ERK1/2 and used to 
generate skin grafts (Fig. 4 A). Whereas cyclin D1–expressing 
cells treated with scrambled siRNA formed normal skin by 6 d 
after grafting, cyclin D1–expressing cells treated with siRNA 
against ERK1/2 formed hypoplastic skin that was indistinguish-
able from skin comprising LacZ-expressing, Erk1/2-depleted 
keratinocytes (Fig. 4, B and C).
Erk1/2 contribute to G1/S progression not only by in-
creasing transcription of G1/S regulators but also by posttrans-
lational  regulation,  including  promotion  of  cyclin  D1–Cdk4 
complex formation (Cheng et al., 1998). The loss of these latter 
Erk1/2 functions may have rendered cyclin D1 overexpression 
unable to rescue the effects of Erk1/2 knockdown in keratino-
cytes. Therefore, to rule out G1/S arrest as the primary cause of 
hypoproliferation in Erk1/2-depleted skin, we attempted to res-
cue the effect of Erk1/2 knockdown by coexpression of cyclin 
D1 and Cdk4-C24, a CA point mutant of Cdk4. This combina-
tion of genes provides a robust method for bypassing G1/S re-
straints in human keratinocytes, including G1 blockade induced 
by oncogenic Ras (Lazarov et al., 2002). Nevertheless, Erk1/2 
depletion in skin overexpressing cyclin D1 and Cdk4-C24 led to 
hypoplasia indistinguishable from that induced by Erk1/2 de-
pletion in control skin expressing LacZ, suggesting that the 
principal effects of Erk1/2 depletion in human skin are on a cell 
cycle stage other than G1/S (Fig. S2, D and E).
Erk1/2 loss induces cell cycle arrest in G2/M 
in epithelial cells and G1/S in fibroblasts
Failure of cyclin D1 and Cdk4-C24 overexpression to rescue 
the cell cycle defect of Erk1/2-depleted keratinocytes suggested 
that this defect involves cell cycle stages other than the G1/S 
transition. Therefore, we investigated the proliferation and cell 
cycle profile of Erk1/2-depleted keratinocytes in vitro. During 
the 7 d after siRNA electroporation, knockdown of Erk1 had no 
effect on keratinocyte proliferation, whereas knockdown of Erk2 
slightly reduced cell division as compared with keratinocytes 
treated with scrambled siRNA. However, simultaneous deple-
tion of Erk1/2 caused a 77% decrease in keratinocyte number, 
which is analogous to its in vivo effects (Fig. 5 A). A second 
pair of siRNA oligomers targeting different regions of ERK1 
and ERK2 (Erk1 + Erk2 [b]) similarly reduced keratinocyte   
proliferation in vitro (Fig. 5, B and C). Consistent with these 
findings, propidium iodide (PI) staining revealed that Erk1/2 
depletion caused a significant decrease in the proportion of ke-
ratinocytes in S phase as compared with control (25.9 vs. 39.9%), 
whereas Erk2 depletion caused a minor reduction in S-phase cells 
(33.6%), and Erk1 depletion had no effect (39.9%; Fig. 5 D). 415 ERK1/2 SUSTAIN G2/M PROGRESSION • Dumesic et al.
Quantitative RT-PCR confirmed that Cdc25C is expressed at 38% 
of its WT level when Erk1/2 are depleted (Fig. S4 A). To deter-
mine whether the decreased expression of Cdc25C could have led 
to the G2/M cell cycle arrest observed in Erk1/2-depleted cells, 
To validate the functional importance of a G2/M regulator 
identified as misexpressed upon Erk1/2 knockdown, we further 
examined Cdc25C, a phosphatase that promotes G2/M progres-
sion by activating the G2/M cyclin-dependent kinase Cdc2. 
Figure 4.  Cyclin D1 does not rescue the effects of epidermal Erk1/2 depletion. (A) Immunoblot of keratinocyte extracts after transduction by the indicated 
retroviral vectors and electroporation with the indicated siRNA stained with the antibodies listed on the right. (B) Mitotic indices of skin grafts comprising 
keratinocytes treated with the indicated siRNA and retroviral vectors. n = 3 grafts per genotype; mean ± SEM; *, P < 0.01 versus control. (C) Human skin 
tissue comprising keratinocytes treated with the indicated siRNA and retroviral vectors, harvested 6 d after grafting, and stained with the antibodies listed 
on the right (orange or green) as well as the nuclear counterstain Hoechst 33342 (blue). Bars, 50 µm.JCB • VOLUME 185 • NUMBER 3 • 2009   416
depletion by expressing a CA form of Cdc25C (Cdc25C-CA) in 
which the residues phosphorylated by Erk1/2 are replaced by 
aspartic acid (Wang et al., 2007). Regenerated human skin ex-
pressing Cdc25C-CA and treated with siRNA against ERK1/2 
showed hypoplasia and hypoproliferation identical to that of 
control skin treated with Erk1/2 siRNA, demonstrating that 
Cdc25C activity alone cannot rescue the effects of Erk1/2 knock-
down on epidermal homeostasis (Fig. S5, C–E).
The inability of Cdc25C activation to rescue the effects of 
Erk1/2 loss suggested that Erk1/2 likely control G2/M progres-
sion via multiple different targets. Indeed, gene network analy-
sis demonstrated that of the 1,205 genes differentially expressed 
we examined the effect of Cdc25C depletion. siRNA targeting 
CDC25C reduced CDC25C mRNA expression to 31% of its WT 
level and induced a G2/M cell cycle arrest in cultured keratino-
cytes  (unpublished  data).  In  vivo  experiments  revealed  that 
Cdc25C knockdown causes epidermal hypoplasia similar to that 
observed upon Erk1/2 depletion, indicating that Cdc25C down-
regulation at levels associated with Erk1/2 depletion are sufficient 
to disrupt epidermal cell cycle progression (Fig. S5, A and B).
We next assessed whether activation of Cdc25C is suffi-
cient to rescue the effects of Erk1/2 depletion in human skin. 
Because Cdc25C is activated transcriptionally and posttransla-
tionally by Erk1/2, we attempted to rescue the effects of Erk1/2 
Figure 5.  Erk1/2 depletion leads to G2/M arrest in epithelial cells but not in fibroblasts. (A) Proliferation kinetics of keratinocytes after electroporation 
with the indicated siRNA. n = 3 per siRNA group per time point; mean ± SEM. (B) Immunoblot of cultured keratinocyte extracts 4 d after electroporation 
with the indicated siRNA, using antibodies listed on the right. (C) Proliferation kinetics of keratinocytes after electroporation with the indicated siRNA. n = 3   
per siRNA group per time point; mean ± SEM. (D) Histograms of PI fluorescence in keratinocytes 4 d after electroporation with the indicated siRNA.   
(E) Immunoblot of fibroblast extracts 4 d after electroporation with the indicated siRNA, using antibodies listed on the right. (F) Histograms of PI fluorescence 
in fibroblasts 4 d after electroporation with indicated siRNA. (G) Immunoblot of fibroblast extracts 4 d after electroporation with the indicated siRNA, using 
the antibodies listed on the right.417 ERK1/2 SUSTAIN G2/M PROGRESSION • Dumesic et al.
in Erk1/2-depleted keratinocytes, 31 encode direct regulators   
or effectors of the core G2/M cyclin-dependent kinase Cdc2 
(Fig. 6 C). Strikingly, of the posttranslational regulators of   
Cdc2, the Cdc2 activators Cdc25A and CCNB1 are both down-
regulated, whereas the Cdc2 inhibitors BTG2, p53, GADD45, 
Wee1, ErbB2, MCL1, CDKN3, and CDKN1B are all up-regulated, 
indicating that gene changes observed in Erk1/2-depleted keratino-
cytes may broadly contribute to G2/M arrest. Consistent with 
this, overexpression of cyclin B1 was insufficient to rescue the 
proliferation defect of keratinocytes lacking Erk1/2, confirming 
that Erk1/2 activity promotes G2/M progression via a broad net-
work of independent mechanisms that cannot be recapitulated by 
activation of any single Erk1/2 effector (Fig. S3 F).
Erk1/2 regulate c-Fos to sustain cyclin  
B1 expression in keratinocytes but not  
in fibroblasts
The finding that G2/M regulatory molecules such as cyclin B1 
are repressed upon Erk1/2 depletion in keratinocytes was sur-
prising given our observation that Erk1/2 knockdown in fibro-
blasts does not induce substantial G2/M arrest, even when the 
G1 arrest induced by Erk1/2 depletion is rescued by cyclin D1 
and Cdk4-C24 overexpression (Fig. S3 A). Therefore, we inves-
tigated whether cyclin B1 expression is suppressed in fibroblasts 
upon Erk1/2 knockdown, as it is in keratinocytes. Immunoblot-
ting revealed that, whereas cyclin B1 protein levels are dramati-
cally reduced upon Erk1/2 knockdown in keratinocytes, Erk1/2 
loss has no effect on cyclin B1 levels in either WT fibroblasts or 
rescued  fibroblasts  overexpressing  cyclin  D1  and  Cdk4-C24 
(Fig. 6 D). This finding, together with the observation that cy-
clin D1 is repressed upon Erk1/2 knockdown in fibroblasts but 
not in keratinocytes (Figs. 4 A and 5 G), confirms that Erk1/2 
regulate cyclin expression in a cell type–specific manner.
To identify Erk1/2 effectors whose differential regulation 
may explain cell type–specific MAPK regulation of cyclin ex-
pression, we examined expression of four canonical Erk1/2 effec-
tors after Erk1/2 depletion in WT keratinocytes, WT fibroblasts, 
or rescued fibroblasts. Whereas Erk1/2 loss had similar effects on 
c-Jun and Elk1 mRNA expression in all cell types, Erk1/2 loss 
decreased c-Myc expression solely in fibroblasts and decreased 
c-Fos expression solely in keratinocytes (Fig. 6, E and F; and   
Fig. S4 B). Erk1/2 loss decreased c-Fos expression similarly in 
WT keratinocytes and keratinocytes expressing cyclin D1 and 
Cdk4-C24, suggesting that expression of these genes did not alter 
c-Fos regulation in rescued fibroblasts (Fig. S3 D). The 75% de-
crease in c-Fos expression in Erk1/2 knockdown keratinocytes 
was associated with a significant decrease in AP-1 reporter activ-
ity (P < 0.05; Fig. S3 E). In contrast, AP-1 reporter activity in WT 
and rescued fibroblasts was increased upon Erk1/2 knockdown. 
Overall, c-Fos expression correlated with AP-1 reporter activity: 
keratinocytes had the lowest level of c-Fos expression upon Erk1/2 
knockdown, as well as the lowest level of AP-1 activity, whereas 
rescued fibroblasts had the highest level of c-Fos expression upon 
Erk1/2 knockdown, as well as the highest level of AP-1 activity.
The finding that Erk1/2 activity sustains c-Fos expression 
uniquely in keratinocytes was striking in light of previous work 
suggesting that c-Fos expression is correlated with cyclin B1 
expression in human endometrial cancers and that Fos binds to 
and positively regulates the cyclin B promoter in Drosophila   
melanogaster (Bamberger et al., 2001; Hyun et al., 2006). To deter-
mine whether c-Fos regulates cyclin B1 expression in human 
cells, as well as the functional importance of this regulation, we 
measured cyclin B1 expression and cell cycle progression in   
keratinocytes and fibroblasts after depletion of c-Fos using siRNA. 
In both cell types, c-Fos loss decreased cyclin B1 expression and 
led to G2/M arrest (Fig. 6, G–I). Importantly, the magnitude of 
G2/M arrest induced by c-Fos knockdown in keratinocytes was 
similar to that induced by Erk1/2 knockdown, confirming that 
c-Fos is a major effector of Erk1/2 signaling in this context. Thus, 
the AP-1 family member c-Fos is required for normal cyclin B1 
expression in human cells, and differential regulation of c-Fos by 
Erk1/2 in keratinocytes versus fibroblasts may contribute to the 
difference in cyclin regulation and cell cycle progression be-
tween these cell types.
Discussion
Using regenerated human skin, we investigated the roles of Erk1 
and Erk2 in regulating epidermal growth and differentiation. 
Depletion of either protein individually caused no abnormal 
phenotype, whereas combined knockdown of Erk1/2 induced 
epidermal hypoplasia and hypoproliferation without disrupting 
differentiation.  Erk1/2-depleted  keratinocytes  exhibited  G2/M 
cell cycle arrest along with deregulation of core G2/M transition 
controllers, including cyclin B1. These findings contrast with the 
G1 arrest and cyclin D1 dysregulation observed in Erk1/2-
depleted fibroblasts, indicating that control of cell cycle progres-
sion by Erk1/2 MAPKs is cell type specific.
Functional redundancy of Erk1 and Erk2
Our findings suggest that the Erk1/2 isoforms possess largely 
overlapping roles in human skin. Erk1 is approximately twice 
as prevalent as Erk2 in normal human skin, but phospho-Erk2 is 
at least as prevalent as phospho-Erk1 in many epithelial tumors, 
suggesting that Erk2 is preferentially activated in this hyper-
proliferative state and may be a more potent mitogen (Pelech, 
2006). Moreover, ERK1 knockout in fibroblasts increases Erk2 
activation and cell proliferation, and overexpression of WT Erk1 
suppresses Erk2 activation and reduces Ras-induced cell prolif-
eration (Vantaggiato et al., 2006). Together, these findings sug-
gest that Erk1 and Erk2 compete for activation by Mek, with 
Erk2 being more active than Erk1, corresponding with our ob-
servation that Erk2 knockdown induces a slight proliferation 
defect (Vantaggiato et al., 2006). However, importantly, Erk1 
knockdown did not increase proliferation of cultured keratino-
cytes, nor did knockdown of either protein affect the mitotic in-
dex of human epidermis in vivo. Assessing the in vivo effects of 
Erk1 or Erk2 knockdown in the setting of constitutive MAPK 
cascade activation and quantifying Erk substrate activation in 
the absence of either Erk1 or Erk2 may be required to detect 
subtle functional differences between these isoforms.
ERK1 knockout mice exhibit hyperplastic epidermis and 
focal cutaneous lesions associated with Escherichia coli infec-
tion, although the phenotype of this animal model is complicated JCB • VOLUME 185 • NUMBER 3 • 2009   418
Figure 6.  Differential regulation of c-Fos by Erk1/2 in keratinocytes and fibroblasts contributes to the distinct cell cycle effects of Erk1/2 knockdown in 
these cell types. (A) Hierarchical clustering of gene expression in keratinocytes treated with the indicated siRNA. Three replicates of each siRNA group are 
shown. Selected genes are labeled on the right. (B) Benjamini-corrected p-values associated with the top seven biological process GO terms most enriched 
in the 1,205 genes identified in A. The dotted line indicates P = 0.05. (C) Map of direct effectors and regulators of Cdc2 that appeared among the 1,205 419 ERK1/2 SUSTAIN G2/M PROGRESSION • Dumesic et al.
with the G1 blockade observed by others upon pharmacologic 
Erk inhibition in fibroblasts that we have reproduced using siRNA 
against Erk1/2 (Meloche and Pouysségur, 2007; Villanueva et al., 
2007). This discrepancy does not represent a general resistance 
of fibroblasts to G2/M-phase arrest because siRNA-mediated 
depletion of a G2/M-phase regulator, Cdc25C, arrested these 
cells in G2/M phase (unpublished data). These findings support 
previous observations of delayed G2/M kinetics upon pharma-
cologic  MAPK  inhibition  in  NIH3T3  cells  and  HeLa  cells 
(Wright et al., 1999; Liu et al., 2004) and imply a substantial 
role for Erk1/2 signaling at multiple points in the cell cycle.
The finding of G2/M arrest upon Erk1/2 blockade in un-
synchronized primary keratinocytes supports previous findings 
in synchronized cell lines (Wright et al., 1999) and emphasizes 
the importance of identifying specific Erk substrates responsible 
for this activity. To that end, our global gene expression analysis 
of Erk1/2-depleted keratinocytes showed substantial misexpres-
sion of G2/M regulators, indicating that broad changes in gene 
expression rather than dysregulation of a single effector likely 
govern the observed G2/M arrest. More specifically, the core 
G2/M regulators, cyclin B1 and cdc2, whose integrated activity is 
essential for mitotic progression, are significantly down-regulated 
along with Cdc25A and Plk1, which are positive regulators of 
the Cdc2–cyclin B1 complex (Fig. 6 C). Simultaneously, nega-
tive regulators of the Cdc2–cyclin B1 complex, including p53, 
GADD45A, and Wee1, are up-regulated with Erk1/2 depletion, 
indicating additional routes by which Erk depletion may cause 
G2/M arrest.
The magnitudes of these gene expression changes are rel-
evant to normal progression through G2/M phase. For instance, 
siRNA-mediated depletion of Cdc25C, which was similar in ex-
tent to that caused by Erk1/2 depletion, caused G2/M arrest in 
cultured keratinocytes and disrupted epidermal homeostasis in 
vivo (Fig. S5). However, given that Erk1/2 affects a broad net-
work of G2/M regulators, it is unlikely that activating a single 
Erk1/2 effector could rescue the effects of Erk1/2 loss in human 
skin. Theoretically, activating the mitosis-promoting factor com-
plex itself (by overexpressing cyclin B1 and a CA mutant of 
Cdc2) could bypass the need for proper expression of G2/M 
regulators and rescue the G2/M arrest observed upon Erk1/2 
knockdown. However, we find that coexpression of these genes 
induces apoptosis in human keratinocytes at early time points 
that preclude analysis of cell cycle effects (unpublished data), 
which agrees with previous results in other cell types and chal-
lenges further attempts to rescue the G2/M blockade induced by 
Erk1/2 loss (Niida et al., 2005).
Because the cell cycle defects induced by Erk1/2 loss in 
fibroblasts can largely be corrected by cyclin D1 and Cdk4-C24 
overexpression, it is likely that Erk1/2 affect G2/M regulators 
differently in this cell type. Indeed, we find that fibroblasts, unlike 
by Erk1 depletion from all tissues and the resulting disruption 
in thymocyte development (Pages et al., 1999; Bourcier et al., 
2006). In our experiments, Erk1-depleted skin grafted onto 
severe combined immunodeficiency mice and maintained under 
sterile conditions did not display abnormal epidermal homeo-
stasis, suggesting that the epidermal hyperplasia of ERK1 
knockout mice might be secondary to altered immune function. 
Alternatively, our experiments assessing Erk1 knockdown over 
1 wk may not have detected subtle proliferation changes. In sup-
port of this, cyclin D1 overexpression under our experimental 
conditions caused mild hyperplasia rather than the pronounced 
hyperplasia noted in human skin grafts maintained for 4 wk 
(Lazarov et al., 2002).
Erk1/2 requirement for epidermal cell cycle 
progression
The phenotype of combined Erk1/2 knockdown in human skin 
mimics the phenotype of skin-specific MEK1/2 double knockout 
mice, as well as the phenotype of combined Mek1/2 knockdown 
in human skin (Scholl et al., 2007). The similarity of these pheno-
types supports the current belief that Erk1/2 are the only effectors 
of Mek1/2 and suggests that these phenotypes represent the effect 
of complete ablation of MAPK cascade signaling. Both models 
were marked by hypoplasia and hypoproliferation despite proper 
expression of basal layer and early differentiation markers. How-
ever, terminal differentiation markers such as loricrin and filag-
grin appeared underexpressed in Erk1/2-depleted epidermis, and 
future studies will be required to assess the long-term effects of 
Erk1/2 loss on epidermal differentiation.
Although an Erk2 construct resistant to Erk2 siRNA re-
versed the effect of Erk1/2 depletion, neither a CA Rsk1 con-
struct nor cyclin D1 overexpression was sufficient to rescue 
the Erk1/2 depletion phenotype. As a direct effector of Erk1/2, 
Rsk1 has pleiotropic roles in the regulation of cell cycle, protein 
synthesis, cell growth, and differentiation (Silverman et al., 2004). 
It promotes G1-phase progression via activation of immediate 
early gene products and drives G2/M-phase progression via in-
hibition of Myt1, a kinase that inhibits Cdc2 (Liu et al., 1999; 
Murphy et al., 2002). Because Rsk1 activation was unable to 
rescue the proliferation defect of Erk1/2-depleted keratinocytes, 
we also attempted to rescue this defect by altering the core cell 
cycle machinery itself via overexpression of cyclin D1 and 
Cdk4-C24. Although this gene combination induces hyperactiv-
ity of the core G1/S cyclin-dependent kinase complex and has 
been previously shown to overcome G1 arrest in human keratino-
cytes (Lazarov et al., 2002, 2003), we observed no rescue of 
Erk1/2 depletion–induced hypoplasia and hypoproliferation, sug-
gesting that Erk actions in this cell type are not limited to the 
G1/S cell cycle stages. Consistent with this, cell cycle analysis re-
vealed a G2/M arrest in Erk1/2-depleted keratinocytes, contrasting 
genes identified in A. Symbols are color-coded according to gene expression levels in Erk1/2-depleted cells as compared with control. (D) Immunoblot of 
keratinocyte, fibroblast, or cyclin D1 + Cdk4-C24–rescued fibroblast extracts 4 d after treatment with the indicated siRNA, using the antibodies listed on 
the right. (E and F) mRNA expression levels of Erk1/2 effectors in keratinocytes (E) or rescued fibroblasts (F) treated with Erk1/2 or scrambled siRNA, as 
measured by quantitative RT-PCR. n = 3 per group; mean ± SEM. (G) mRNA expression levels of c-Fos and cyclin B1 in keratinocytes and fibroblasts treated 
with c-Fos or scrambled siRNA, as measured by quantitative RT-PCR. n = 3 per group; mean ± SEM. (H and I) Histograms of PI fluorescence in keratinocytes 
(H) or fibroblasts (I) 4 d after electroporation with the indicated siRNA.
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as previously described (Kinsella and Nolan, 1996). Cells were infected 
for 1 h in the presence of 5 µg/ml polybrene and concomitantly centri-
fuged at 300 g and 32°C. Keratinocytes were infected once, whereas 
fibroblasts were infected twice, 12 h apart. To confirm gene knockdown 
and transduction efficiency, infected cells were cultured in keratinocyte   
serum-free medium (Invitrogen) until 4 d after siRNA electroporation, at which 
point they were harvested for immunoblot analysis.
Protein expression analysis
Keratinocyte and fibroblast cell lysis and immunoblotting were performed as 
described previously (Scholl et al., 2007). Primary antibodies used included 
rabbit anti–p44/p42 MAPK (1:1,000; Cell Signaling Technology), rabbit 
anti-phospho–p44/p42 MAPK (1:1,000; Cell Signaling Technology), rab-
bit  anti–-galactosidase  (1:20,000  MP  Biomedicals),  rabbit  anti-Rsk1 
(1:200; Millipore), rabbit anti–phospho-573–Rsk1 (1:1,000; Cell Signaling 
Technology),  mouse  anti–cyclin  D1  (1:1,000,  BD),  rabbit  anti-Cdc25C 
(1:1,000;  Cell  Signaling  Technology),  mouse  anti–cyclin  B1  (1:1,000; 
Santa Cruz Biotechnology, Inc.), and mouse anti–-actin (1:5,000, Sigma-
Aldrich).  Secondary  antibodies  used  were  horseradish  peroxidase– 
conjugated donkey anti–rabbit IgG and sheep anti–mouse IgG (1:20,000; 
GE Healthcare). Supersignal Pico and Supersignal Dura (Thermo Fisher Sci-
entific) were used as chemiluminescence reagents, and film (XAR Biomax; 
Kodak) was used for detection. Multiple proteins were detected on the 
same membrane by incubating membranes in stripping buffer (100 mM   
-mercaptoethanol, 2% SDS, and 62.5 mM Tris at pH 6.8) for 20 min at 
55°C and then restaining them.
Immunostaining, immunohistochemistry, and histology
For immunostaining, human skin tissue was frozen in Optimal Cutting Tem-
perature compound (Sakura Finetek) and subsequently cut into 7-µm cryo-
sections and fixed in 20°C acetone for 10 min. For blocking, sections 
were incubated for 1 h with 10% horse serum in PBS; next, sections were 
incubated for 1 h with primary antibody and 2% horse serum in PBS, after 
which they were washed with PBS. Finally, sections were incubated for 1 h 
with secondary antibody, 2% horse serum, and 2 mg/ml Hoechst 33342 
nuclear dye (Invitrogen) in PBS, after which they were washed with   
PBS and mounted in Prolong Gold mounting medium (Invitrogen). Primary 
antibodies used included mouse anti–human desmoglein 3 (1:200; Invit-
rogen), rabbit anti–human Ki-67 (1:100; NeoMarkers), mouse anti–1 in-
tegrin (1:100; Santa Cruz Biotechnology, Inc.), rabbit anti–mouse keratin 5 
(1:1,000; Covance), rabbit anti–mouse keratin 10 (1:500; Covance), 
and  rabbit  anti–transglutaminase  1  (1:100;  Biomedical  Technologies, 
Inc.). Donkey anti–rabbit Cy3 IgG (1:100; Jackson ImmunoResearch Lab-
oratories),  goat  anti–mouse  Alexa  Fluor  555  (1:500,  Invitrogen),  and 
goat anti–mouse Alexa Fluor 488 (1:500; Invitrogen) were used as sec-
ondary antibodies.
For immunohistochemistry and histology, human skin grafts were 
fixed in 10% neutral buffered formalin (Sigma-Aldrich) and embedded in 
paraffin, from which 5-µm sections were cut and stained with hematoxylin 
and eosin (H&E) or by immunohistochemistry according to standard meth-
ods. Permeabilization for antigen retrieval was achieved by microwaving 
samples in Antigen Unmasking Solution (Vector Laboratories), after which 
the sections were stained with rabbit anti–p44/p42 total MAPK 137F5 
(1:250; Cell Signaling Technology) as primary antibody and biotinylated 
horse anti–rabbit IgG as secondary antibody (RTU Vectastain Universal 
Elite ABC kit; Vector Laboratories). Staining and development were per-
formed using the Elite ABC Reagent (Vector Laboratories) and liquid DAB
+ 
substrate chromogen system (Dako).
For TUNEL apoptosis staining, 7-µm cryosections were fixed in room 
temperature 4% paraformaldehyde for 20 min followed by 30 min in PBS 
and 2 min in 100% ethanol. Subsequently, TUNEL enzymatic labeling was 
performed using the In situ Cell Death Detection kit, TMR red (Roche).
Cell proliferation assay, cell cycle analysis, and AP-1 reporter assay
To monitor keratinocyte proliferation, cells cultured in keratinocyte serum-free 
medium were electroporated with siRNA and, 1 d later, plated into 6-cm 
dishes at a density of 4 × 10
4 cells per plate. Total cell number per plate was 
determined 3, 5, and 7 d later by trypsinizing each plate’s keratinocytes and 
counting them in a hemocytometer (Hausser Scientific). For cell cycle analy-
sis, keratinocytes were cultured in keratinocyte serum-free medium, and pri-
mary human dermal fibroblasts were cultured in Dulbecco’s modified Eagle’s 
medium (Invitrogen) with 10% fetal bovine serum; each medium contained 
100 U/ml penicillin and 100 µg/ml streptomycin. 4 d after siRNA electro-
poration, cells were harvested, and PI staining was performed as previously 
described (Truong et al., 2006). Watson model cell cycle analysis was per-
formed using FlowJo 8.4.5 software (Tree Star, Inc.).
keratinocytes, down-regulate cyclin D1 but not cyclin B1 upon 
Erk1/2 loss. Our experiments indicate that differential regula-
tion of c-Fos may explain this finding, as Erk1/2 are required for 
c-Fos expression and AP-1 activity in keratinocytes but not   
fibroblasts. Furthermore, with the two AP-1–binding sites in the 
Drosophila CycB promoter being conserved in the human ge-
nome (Hyun et al., 2006), we find that c-Fos is required for nor-
mal cyclin B1 expression and G2/M-phase progression in both 
human keratinocytes and fibroblasts.
In summary, although Erk1 and Erk2 demonstrate func-
tional redundancy in human epidermis in vivo, combined deple-
tion of Erk1/2 disrupts epidermal homeostasis, indicating that 
Erk1/2 signaling is absolutely required in this setting. Tissue 
lacking Erk1/2 is markedly hypoplastic and hypoproliferative. 
These  defects  are  not  rescued  by  activation  of  a  pleiotropic 
Erk1/2 effector, Rsk1, or by activation of the core G1/S cyclin-
dependent kinase complex, indicating that Erk1/2 use alternate 
mechanisms to control cell cycle progression in this setting. In-
deed, Erk1/2 depletion in keratinocytes is marked by G2/M ar-
rest and dysregulated expression of a gene regulatory network, 
including the Cdc2–cyclin B1 complex and many of its regula-
tors. In contrast, Erk1/2 depletion in fibroblasts induces G1 
arrest that can be suppressed by expressing cyclin D1 and 
Cdk4-C24, indicating that the mechanisms by which Erk1/2 
regulate cell cycle progression vary by cell type. In this regard, 
we found that expression of c-Fos, which controls cyclin B1 lev-
els and G2/M progression in both keratinocytes and fibroblasts, 
is Erk1/2 dependent only in keratinocytes. These findings indi-
cate that Erk1/2 act in the epidermis as an essential, functionally 
redundant regulator of homeostasis that sustains basal cell pro-
liferation by promoting G2/M progression.
Materials and methods
RNAi and gene transfer in regenerated human skin
Multiple  independent  sets  of  siSTABLE  siRNA  oligomers  against  ERK1, 
ERK2, CDC25C, and FOS, as well as an siSTABLE scrambled control oligo-
mer, were synthesized by Thermo Fisher Scientific. These oligomers were 
delivered to primary human foreskin keratinocytes by electroporation using 
a Nucleofector II (Amaxa). In each nucleofection, 10
6 keratinocytes were 
electroporated with 1.4 nmol control oligomer, 0.7 nmol Erk1 oligomer and 
0.7 nmol control oligomer, 0.7 nmol Erk2 oligomer and 0.7 nmol control 
oligomer, or 0.7 nmol Erk1 oligomer and 0.7 nmol Erk2 oligomer. To gener-
ate a human skin graft, 3.5 × 10
5 siRNA-treated keratinocytes were seeded 
onto a 2-cm
2 piece of devitalized human dermis and cultured in keratino-
cyte growth medium for 2 d, at which point the dermis piece was grafted 
onto a 6- to 8-wk-old female CB-17 severe combined immunodeficiency 
mouse as previously described (Choate et al., 1996; Scholl et al., 2007). 
Skin grafts were harvested 6 d after surgery. All animal protocols were ap-
proved by the Stanford University Animal Care and Use Committee.
For  rescue  experiments,  keratinocytes  or  primary  human  dermal   
fibroblasts were transduced 2 d before siRNA electroporation with LZRS-
LacZ,  LZRS–Erk2-CA,  LZRS–Erk2-WT,  LZRS–Rsk1-CA,  LZRS–cyclin  D1, 
LZRS–Cdk4-C24, or LZRS–Cdc25C-CA. LacZ, Erk2-CA, cyclin D1, and Cdk4-
C24 retroviral vectors were prepared as described previously (Kinsella and 
Nolan, 1996; Lazarov et al., 2002; Scholl et al., 2007), whereas the 
Erk2-WT, Rsk1-CA, and Cdc25C-CA vectors were constructed by cloning 
of the coding sequence of each gene into pENTR1A, from which it was 
transferred into the LZRS vector by an LR Clonase reaction (Gateway Tech-
nologies; Emrick et al., 2001; Silverman et al., 2004). The plasmid used 
to generate the Rsk1-CA vector was provided by J. Maller (University of 
Colorado Health Science Center, Denver, CO), and the plasmid used to 
generate the Erk2-CA vector was provided by N. Ahn (University of Colo-
rado, Boulder, CO). Viral packaging was performed in 293T Phoenix cells 421 ERK1/2 SUSTAIN G2/M PROGRESSION • Dumesic et al.
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To measure the effect of Erk1/2 loss on AP-1 activity, 10
6 keratino-
cytes or fibroblasts were electroporated with 1,400 nmol siRNA, 3 µg pAP-
1-Luc (Agilent Technologies), and 60 ng CMV-RU Renilla plasmid. 2 d after 
electroporation,  30  ng/ml  TPA  (12-O-tetradecanoylphorbol-13-acetate) 
was added to the cell media to stimulate AP-1 activity. 1 d later, the cells 
were harvested using the Dual-Luciferase Reporter Assay System (Promega). 
Luciferase activity was normalized to Renilla activity; the resulting ratios 
were normalized to control samples.
mRNA expression analysis
Microarray analysis was performed on primary human keratinocytes har-
vested 4 d after siRNA electroporation. Cells were lysed in TRIZOL reagent 
(Invitrogen), and RNA was subsequently isolated from the aqueous phase 
using an RNeasy kit (QIAGEN). The Stanford Protein and Nucleic Acid 
Facility performed cDNA amplification, labeling, and hybridization to 
HG-U133A2.0 microarray chips (Affymetrix). Data were analyzed using 
GeneSpring GX (Agilent Technologies) and Ingenuity Pathways Analysis 6 
software (Ingenuity Systems).
For  quantitative  RT-PCR,  RNA  was  isolated  using  TRIZOL  and  an 
RNeasy kit as described in the previous paragraph; it was then treated with 
RNaseOUT and DNase I (Invitrogen). Reactions were performed using an 
Mx3000P (Agilent Technologies) instrument and the Brilliant SYBR Green QRT-
PCR Master Mix kit (Agilent Technologies). 100 ng RNA was amplified per re-
action in the presence of 100 nM of each primer (Fig. S4 C). Each reaction 
was normalized to levels of GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) mRNA. Microarray data are publicly available in the Gene Expres-
sion Omnibus under accession no. GSE15417.
Statistics
In  Erk1/2  knockdown  experiments,  mitotic  indices  were  compared  by 
analysis of variance, and subsequent post hoc analyses were made using 
Tukey’s test. In rescue experiments, Student’s t test was used to compare mi-
totic indices.
Image acquisition and manipulation
Immunostained sections were viewed using a microscope (100M Axio-
vert; Carl Zeiss, Inc.) with a 40× Plan-Neofluar /0.75 objective (Carl 
Zeiss, Inc.), and micrographs were captured using a camera (Axiocam; 
Carl Zeiss, Inc.) and Openlab 5.0.1 software (PerkinElmer). H&E-stained 
sections were viewed using a microscope (DM LB; Leica) with a 40× N 
Plan /0.65 objective (Leica). Images were captured using a camera 
(SPOT Insight QE; Diagnostic Instruments, Inc.) and SPOT 4.5.9.12 soft-
ware (Diagnostic Instruments, Inc.). All images were captured at room 
temperature. Photoshop CS3 (Adobe) was used to adjust image bright-
ness and contrast.
Online supplemental material
Fig. S1 shows Erk1/2 expression and TUNEL staining in regenerated 
human epidermis treated with Erk1/2 siRNA. Fig. S2 shows that expression 
of WT Erk2 but not expression of cyclin D1 and CA Cdk4 is sufficient to 
rescue the in vivo effects of epidermal Erk1/2 knockdown. Fig. S3 shows 
that expression of cyclin D1 and CA Cdk4 suppresses the cell cycle defect 
caused by Erk1/2 depletion in fibroblasts but not in keratinocytes and 
shows the effect of Erk1/2 knockdown on AP-1 reporter activity in keratino-
cytes and fibroblasts. Fig. S4 illustrates the effect of Erk1/2 knockdown 
on expression of G2/M-phase regulators and transcription factors in kera-
tinocytes and fibroblasts and lists the quantitative RT-PCR primers used in 
this study. Fig. S5 shows that depletion of the Erk1/2 effector Cdc25C is 
sufficient to induce epidermal hypoplasia, whereas overexpression of 
CA Cdc25C does not rescue the effects of epidermal Erk1/2 knockdown 
in vivo. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200804038/DC1.
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